Galectin-3 in Renal Pathology: More Than Just an Innocent Bystander?

American Journal of Nephrology

Volumn 43, Issue 5, 2016, Pages 305-317

  Desmedt, Valerie ^a   Desmedt, Stephanie ^a   Delanghe, Joris R ^a   Speeckaert, Reinhart ^a   Speeckaert, Marijn M ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Galectin 3; Kidney disease; Lectin; Renal fibrosis

Indexed keywords

ALDOSTERONE; DX 52 1; GALECTIN 3; HUK 921; MUCIN 1; PECTIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; CARDIORENAL SYNDROME; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL MEDITERRANEAN FEVER; GLOMERULONEPHRITIS; HEMODIALYSIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CARCINOMA; KIDNEY CORTEX; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM;

ANIMALS; GALECTIN 3; HUMANS; KIDNEY DISEASES;

EID: 84966774788     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000446376     Document Type: Review

References (91)

1. Vijayakumar S, Peng H, Schwartz GJ: Galectin-3 mediates oligomerization of secreted hensin using its carbohydrate-recognition domain. Am J Physiol Renal Physiol 2013; 305:F90-F99.
2. Poland PA, Rondanino C, Kinlough CL, et al: Identification and characterization of endogenous galectins expressed in Madin Darby canine kidney cells. J Biol Chem 2011; 286: 6780-6790.
3. Friedrichs J, Manninen A, Muller DJ, Helenius J: Galectin-3 regulates integrin alpha2beta1-mediated adhesion to collagen-I and-IV. J Biol Chem 2008; 283: 32264-32272.
4. Fernandes Bertocchi AP, Campanhole G, Wang PH, et al: A role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. Transpl Int 2008; 21: 999-1007.
5. Nio J, Takahashi-Iwanaga H, Morimatsu M, Kon Y, Iwanaga T: Immunohistochemical and in situ hybridization analysis of galectin-3, a beta-galactoside binding lectin, in the urinary system of adult mice. Histochem Cell Biol 2006; 126: 45-56.
6. Bao Q, Hughes RC: Galectin-3 expression and effects on cyst enlargement and tubulogenesis in kidney epithelial MDCK cells cultured in three-dimensional matrices in vitro. J Cell Sci 1995; 108(pt 8):2791-2800.
7. Nieminen J, Kuno A, Hirabayashi J, Sato S: Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. J Biol Chem 2007; 282: 1374-1383.
8. Lepur A, Salomonsson E, Nilsson UJ, Leffler H: Ligand induced galectin-3 protein self-association. J Biol Chem 2012; 287: 21751-21756.
9. von Mach T, Carlsson MC, Straube T, Nilsson U, Leffler H, Jacob R: Ligand binding and complex formation of galectin-3 is modulated by pH variations. Biochem J 2014; 457: 107-115.
10. Schwaderer AL, Vijayakumar S, Al-Awqati Q, Schwartz GJ: Galectin-3 expression is induced in renal beta-intercalated cells during metabolic acidosis. Am J Physiol Renal Physiol 2006; 290:F148-F158.
11. Winyard PJ, Bao Q, Hughes RC, Woolf AS: Epithelial galectin-3 during human nephrogenesis and childhood cystic diseases. J Am Soc Nephrol 1997; 8: 1647-1657.
12. Liu FT, Patterson RJ, Wang JL: Intracellular functions of galectins. Biochim Biophys Acta 2002; 1572: 263-273.
13. Van den Brule FA, Fernandez PL, Buicu C, et al: Differential expression of galectin-1 and galectin-3 during first trimester human embryogenesis. Dev Dyn 1997; 209: 399-405.
14. Colnot C, Fowlis D, Ripoche MA, Bouchaert I, Poirier F: Embryonic implantation in galectin 1/galectin 3 double mutant mice. Dev Dyn 1998; 211: 306-313.
15. Vasta GR: Galectins as pattern recognition receptors: structure, function, and evolution. Adv Exp Med Biol 2012; 946: 21-36.
16. Kuklinski S, Probstmeier R: Homophilic binding properties of galectin-3: involvement of the carbohydrate recognition domain. J Neurochem 1998; 70: 814-823.
17. Straube T, von Mach T, Honig E, Greb C, Schneider D, Jacob R: pH-dependent recycling of galectin-3 at the apical membrane of epithelial cells. Traffic 2013; 14: 1014-1027.
18. Christenson RH, Duh SH, Wu AH, et al: Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin Biochem 2010; 43: 683-690.
19. Gaze DC, Prante C, Dreier J, et al: Analytical evaluation of the automated galectin-3 assay on the Abbott ARCHITECT immunoassay instruments. Clin Chem Lab Med 2014; 52: 919-926.
20. Gruson D, Mancini M, Ahn SA, Rousseau MF: Galectin-3 testing: validity of a novel automated assay in heart failure patients with reduced ejection fraction. Clin Chim Acta 2014; 429: 189-193.
21. Lameire N, Van Biesen W, Vanholder R: Acute renal failure. Lancet 2005; 365: 417-430.
22. Lameire N: The definitions and staging systems of acute kidney injury and their limitations in practice. Arab J Nephrol Transplant 2013; 6: 145-152.
23. Nishiyama J, Kobayashi S, Ishida A, et al: Up-regulation of galectin-3 in acute renal failure of the rat. Am J Pathol 2000; 157: 815-823.
24. Tang WH, Shrestha K, Shao Z, et al: Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011; 108: 385-390.
25. O'Seaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D, Fox CS: Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol 2013; 24: 1470-1477.
26. Iacoviello M, Aspromonte N, Leone M, et al: Galectin-3 serum levels are independently associated with microalbuminuria in chronic heart failure outpatients. Res Cardiovasc Med 2015; 5:e28952.
27. Bansal N, Katz R, Seliger S, et al: Galectin-3 and soluble ST2 and kidney function decline in older adults: the Cardiovascular Health Study (CHS). Am J Kidney Dis 2016;pii :S0272-6386(16)00013-5.
28. Meijers WC, van der Velde AR, Ruifrok WP, et al: Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis. J Am Heart Assoc 2014; 3:e000962.
29. Savic J, Zeljkovic A, Bogavac-Stanojevic N, et al: Association of small, dense low-density lipoprotein cholesterol and galectin-3 in patients with chronic kidney disease. Scand J Clin Lab Invest 2014; 74: 637-643.
30. Hogas S, Schiller A, Voroneanu L, et al: Predictive value for galectin 3 and cardiotrophin 1 in hemodialysis patients. Angiology 2016;pii:0003319715623397.
31. Vlassara H: Protein glycation in the kidney: role in diabetes and aging. Kidney Int 1996; 49: 1795-1804.
32. Pugliese G, Iacobini C, Pesce CM, Menini S: Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology 2015; 25: 136-150.
33. Vlassara H, Li YM, Imani F, et al: Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995; 1: 634-646.
34. Pugliese G, Pricci F, Iacobini C, et al: Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J 2001; 15: 2471-2479.
35. Iacobini C, Menini S, Oddi G, et al: Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J 2004; 18: 1773-1775.
36. Kikuchi Y, Kobayashi S, Hemmi N, et al: Galectin-3-positive cell infiltration in human diabetic nephropathy. Nephrol Dial Transplant 2004; 19: 602-607.
37. Drechsler C, Delgado G, Wanner C, et al: Galectin-3, renal function, and clinical outcomes: results from the LURIC and 4D studies. J Am Soc Nephrol 2015; 26: 2213-2221.
38. Jeon SB, Yoon HJ, Chang CY, Koh HS, Jeon SH, Park EJ: Galectin-3 exerts cytokine-like regulatory actions through the JAK-STAT pathway. J Immunol 2010; 185: 7037-7046.
39. Watson AM, Li J, Samijono D, et al: Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice. Atherosclerosis 2014; 235: 444-448.
40. Cucak H, Nielsen Fink L, Hojgaard Pedersen M, Rosendahl A: Enalapril treatment increases T cell number and promotes polarization towards M1-like macrophages locally in diabetic nephropathy. Int Immunopharmacol 2015; 25: 30-42.
41. de Boer RA, van Veldhuisen DJ, Gansevoort RT, et al: The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012; 272: 55-64.
42. Gasparitsch M, Arndt AK, Pawlitschek F, et al: RAGE-mediated interstitial fibrosis in neonatal obstructive nephropathy is independent of NF-?B activation. Kidney Int 2013; 84: 911-919.
43. Henderson NC, Mackinnon AC, Farnworth SL, et al: Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008; 172: 288-298.
44. Dang Z, MacKinnon A, Marson LP, Sethi T: Tubular atrophy and interstitial fibrosis after renal transplantation is dependent on galectin-3. Transplantation 2012; 93: 477-484.
45. Okamura DM, Pasichnyk K, Lopez-Guisa JM, et al: Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol 2011; 300:F245-F253.
46. Li LC, Li J, Gao J: Functions of galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther 2014; 351: 336-343.
47. Vansthertem D, Cludts S, Nonclercq D, et al: Immunohistochemical localization of galectins-1 and-3 and monitoring of tissue galectin-binding sites during tubular regeneration after renal ischemia reperfusion in the rat. Histol Histopathol 2010; 25: 1417-1429.
48. Tumlin JA, Costanzo MR, Chawla LS, et al: Cardiorenal syndrome type 4: insights on clinical presentation and pathophysiology from the eleventh consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol 2013; 182: 158-173.
49. Hundae A, McCullough PA: Cardiac and renal fibrosis in chronic cardiorenal syndromes. Nephron Clin Pract 2014; 127: 106-112.
50. Sharma UC, Pokharel S, van Brakel TJ, et al: Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110: 3121-3128.
51. Lin YH, Lin LY, Wu YW, et al: The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009; 409: 96-99.
52. Gopal DM, Kommineni M, Ayalon N, et al: Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc 2012; 1:e000760.
53. Winyard PJ, Bao Q, Hughes RC, Woolf AS: Epithelial galectin-3 during human nephrogenesis and childhood cystic diseases. J Am Soc Nephrol 1997; 8: 1647-1657.
54. Bullock SL, Johnson TM, Bao Q, Hughes RC, Winyard PJ, Woolf AS: Galectin-3 modulates ureteric bud branching in organ culture of the developing mouse kidney. J Am Soc Nephrol 2001; 12: 515-523.
55. Hikita C, Vijayakumar S, Takito J, Erdjument-Bromage H, Tempst P, Al-Awqati Q: Induction of terminal differentiation in epithelial cells requires polymerization of hensin by galectin 3. J Cell Biol 2000; 151: 1235-1246.
56. Guay-Woodford LM, Desmond RA: Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics 2003; 111(5 pt 1):1072-1080.
57. Bao Q, Hughes RC: Galectin-3 and polarized growth within collagen gels of wild-type and ricin-resistant MDCK renal epithelial cells. Glycobiology 1999; 9: 489-495.
58. Chiu MG, Johnson TM, Woolf AS, et al: Galectin-3 associates with the primary cilium and modulates cyst growth in congenital polycystic kidney disease. Am J Pathol 2006; 169: 1925-1938.
59. Huang CS, Tang SJ, Chung LY, et al: Galectin-1 upregulates CXCR4 to promote tumor progression and poor outcome in kidney cancer. J Am Soc Nephrol 2014; 25: 1486-1495.
60. Kaneko N, Gotoh A, Okamura N, et al: Potential tumor markers of renal cell carcinoma: ?-enolase for postoperative follow up, and galectin-1 and galectin-3 for primary detection. Int J Urol 2013; 20: 530-535.
61. Straube T, Elli AF, Greb C, et al: Changes in the expression and subcellular distribution of galectin-3 in clear cell renal cell carcinoma. J Exp Clin Cancer Res 2011; 30: 89.
62. Sakaki M, Fukumori T, Fukawa T, et al: Clinical significance of galectin-3 in clear cell renal cell carcinoma. J Med Invest 2010; 57: 152-157.
63. von Klot CA, Kramer MW, Peters I, et al: Galectin-1 and galectin-3 mRNA expression in renal cell carcinoma. BMC Clin Pathol 2014; 14: 15.
64. Dancer JY, Truong LD, Zhai Q, Shen SS: Expression of galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker. Arch Pathol Lab Med 2010; 134: 90-94.
65. Bing Z, Lal P, Lu S, Ziober A, Tomaszewski JE: Role of carbonic anhydrase IX, ?-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study. Ann Diagn Pathol 2013; 17: 58-62.
66. Merseburger AS, Kramer MW, Hennenlotter J, et al: Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World J Urol 2008; 26: 637-642.
67. Takenaka Y, Fukumori T, Raz A: Galectin-3 and metastasis. Glycoconj J 2004; 19: 543-549.
68. Xu Y, Gu X, Gong M, Guo G, Han K, An R: Galectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment. Cancer Biol Ther 2013; 14: 897-906.
69. Ostalska-Nowicka D, Nowicki M, Kondraciuk B, Partyka M, Samulak D, Witt M: Expression of galectin-3 in nephrotic syndrome glomerulopaties in children. Folia Histochem Cytobiol 2009; 47: 315-322.
70. Kang EH, Moon KC, Lee EY, et al: Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. Lupus 2009; 18: 22-28.
71. Sasaki S, Bao Q, Hughes RC: Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J Pathol 1999; 187: 481-489.
72. Ponticelli C, Villa M, Cesana B, Montagnino G, Tarantino A: Risk factors for late kidney allograft failure. Kidney Int 2002; 62: 1848-1854.
73. Tan R, Liu X, Wang J, et al: Alternations of galectin levels after renal transplantation. Clin Biochem 2014; 47: 83-88.
74. Yilmaz H, Inan O, Darcin T, Bilgic MA, Akcay A: Serum galectin-3 levels were associated with proteinuria in patients with familial Mediterranean fever. Clin Exp Nephrol 2015; 19: 436-442.
75. Drenth JP, van der Meer JW: Hereditary periodic fever. N Engl J Med 2001; 345: 1748-1757.
76. Al-Salam S, Conca W: Novel protagonists in autoinflammatory arthritis of familial Mediterranean fever. Pediatrics 2011; 128:e464-e470.
77. Artini M, Natoli C, Tinari N, et al: Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol 1996; 25: 212-217.
78. Longo G, Natoli C, Rafanelli D, et al: Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. Br J Haematol 1993; 85: 207-209.
79. Lin YH, Lin LY, Wu YW, et al: The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009; 409: 96-99.
80. Hepojoki J, Strandin T, Hetzel U, et al: Acute hantavirus infection induces galectin-3-binding protein. J Gen Virol 2014; 95(pt 11):2356-2364.
81. Altman E, Harrison BA, Latta RK, Lee KK, Kelly JF, Thibault P: Galectin-3-mediated adherence of Proteus mirabilis to Madin-Darby canine kidney cells. Biochem Cell Biol 2001; 79: 783-788.
82. Hart PD, Bakris GL: Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother 2010; 11: 2675-2686.
83. Frenay AR, Yu L, van der Velde AR, Vreeswijk-Baudoin I, et al: Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy. Am J Physiol Renal Physiol 2015; 308:F500-F509.
84. Traber PG, Zomer E: Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One 2013; 8:e83481.
85. Nangia-Makker P, Hogan V, Honjo Y, et al: Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 2002; 94: 1854-1862.
86. Inohara H, Raz A: Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J 1994; 11: 527-532.
87. Ridley BL, O'Neill MA, Mohnen D: Pectins: structure, biosynthesis, and oligogalacturonide-related signaling. Phytochemistry 2001; 57: 929-967.
88. Gunning AP, Bongaerts RJ, Morris VJ: Recognition of galactan components of pectin by galectin-3. FASEB J 2009; 23: 415-424.
89. Kolatsi-Joannou M, Price KL, Winyard PJ, Long DA: Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS One 2011; 6:e18683.
90. Kahsai AW, Cui J, Kaniskan HU, Garner PP, Fenteany G: Analogs of tetrahydroisoquinoline natural products that inhibit cell migration and target galectin-3 outside of its carbohydrate-binding site. J Biol Chem 2008; 283: 24534-24545.
91. Calvier L, Martinez-Martinez E, Miana M, et al: The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail 2015; 3: 59-67.